This Week in NEJM | GenomeWeb

This Week in NEJM

Premium

In NEJM this week, researchers in the UK report on the efficacy of radiotherapy for the treatment of muscle-invasive bladder cancer. The team randomly assigned 360 bladder cancer patients to undergo radiotherapy with or without synchronous chemotherapy. The two-year locoregional disease-free survival rate for the combination radiotherapy/chemotherapy group was 67 percent compared to 54 percent for the radiotherapy alone group, the team found.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.